Department of Medical and Molecular Genetics, Indiana University School of Medicine, 975 West Walnut Street, Indianapolis, IN 46202, USA.
Best Pract Res Clin Rheumatol. 2011 Oct;25(5):735-47. doi: 10.1016/j.berh.2011.10.020.
Familial tumoral calcinosis (TC) is a rare disorder distinguished by the development of ectopic and vascular calcified masses that occur in settings of hyperphosphatemia (hFTC) and normophosphatemia (nFTC). Serum phosphorus concentrations are relatively tightly controlled by interconnected endocrine activity at the level of the intestine, kidney, and skeleton. Discovering the molecular causes for heritable forms of hFTC has shed new light on the regulation of serum phosphate balance. This review will focus upon the genetic basis and clinical approaches for hFTC, due to genes that are related to the phosphaturic hormone fibroblast growth factor-23 (FGF23). These include FGF23 itself, an FGF23-glycosylating enzyme (GALNT3), and the FGF23 co-receptor α-Klotho (αKL). Our understanding of the molecular basis of hFTC will, in the short term, aid in understanding normal phosphate balance, and in the future, provide potential insight into the design of novel therapeutic strategies for both rare and common disorders of phosphate metabolism.
家族性肿瘤性钙质沉着症(TC)是一种罕见疾病,其特征是在高磷血症(hFTC)和正常磷血症(nFTC)环境下发生异位和血管钙化肿块。血清磷浓度由肠道、肾脏和骨骼的内分泌相互作用来进行相对严格的控制。对遗传性 hFTC 的分子病因的发现为血清磷酸盐平衡的调节提供了新的线索。这篇综述将重点介绍 hFTC 的遗传基础和临床方法,因为这些方法与磷酸尿激素成纤维细胞生长因子-23(FGF23)有关。这些包括 FGF23 本身、FGF23 糖基化酶(GALNT3)和 FGF23 共受体 α-Klotho(αKL)。我们对 hFTC 分子基础的理解将在短期内有助于理解正常的磷酸盐平衡,并在未来为设计新型治疗策略提供潜在的见解,这些策略既适用于罕见的磷酸盐代谢紊乱,也适用于常见的磷酸盐代谢紊乱。